This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase II Iressa & Carbo/Gem in NSCLC

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: December 12, 2005
Last updated: June 11, 2009
Last verified: June 2009
The primary objective is to demonstrate in chemotherapy naïve patients with advanced (Stage IIIB or IV) NSCLC and ECOG PS 2 non-inferiority in progression free survival (PFS) for ZD1839 compared to gemcitabine/carboplatin.

Condition Intervention Phase
Carcinoma, Non-Small-Cell Lung Drug: Gefitinib Drug: Gemcitabine Drug: Carboplatin Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-Label Phase II Study Of ZD1839 (IRESSA™) Versus Gemcitabine And Carboplatin In Chemotherapy-Naive Patients With Advanced (Stage IIIB OR IV) Non-Small Cell Lung Cancer And ECOG Performance Status 2

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Progression Free Survival (PFS) [ Time Frame: Date of randomization to earliest date of objective disease progression ]

Enrollment: 38
Study Start Date: October 2004
Study Completion Date: June 2008
Arms Assigned Interventions
Active Comparator: 1
Gemcitabine + Carboplatin
Drug: Gemcitabine
intravenous injection
Other Name: Gemzar
Drug: Carboplatin
intravenous injection
Other Name: CBDCA
Experimental: 2
Drug: Gefitinib
oral tablet
Other Names:
  • ZD1839


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Advanced Non Small cell Lung Cell Lung cancer
  • Never received chemotherapy
  • Up and about 50% of waking hours

Exclusion Criteria:

  • Spread of lung cancer to the brain
  • Low level of white blood cells
  • Radiotherapy within 4 weeks

Patients were entered to this study, initiated in 2004, before the significance of predictive factors such as smoking history, adenocarcinoma histology and mutation status was described.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00264498

Canada, Quebec
Research Site
Montreal, Quebec, Canada
Sponsors and Collaborators
Study Director: AstraZeneca Canada Oncology Medical Director, MD AstraZeneca
  More Information Identifier: NCT00264498     History of Changes
Other Study ID Numbers: 1839IL/0551
Study First Received: December 12, 2005
Results First Received: June 11, 2009
Last Updated: June 11, 2009

Keywords provided by AstraZeneca:
Non-Small-Cell Lung Cancer
Lung Cancer

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Protein Kinase Inhibitors processed this record on September 19, 2017